Literature DB >> 25418070

Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis.

Mattia Cocco1, Davide Garella, Antonella Di Stilo, Emily Borretto, Livio Stevanato, Marta Giorgis, Elisabetta Marini, Roberto Fantozzi, Gianluca Miglio, Massimo Bertinaria.   

Abstract

Pyroptosis is a caspase-1-dependent pro-inflammatory form of programmed cell death implicated in the pathogenesis of autoinflammatory diseases as well as in disorders characterized by excessive cell death and inflammation. Activation of NLRP3 inflammasome is a key event in the pyroptotic cascade. In this study, we describe the synthesis and chemical tuning of α,β-unsaturated electrophilic warheads toward the development of antipyroptotic compounds. Their pharmacological evaluation and structure-activity relationships are also described. Compound 9 was selected as a model of this series, and it proved to be a reactive Michael acceptor, irreversibly trapping thiol nucleophiles, which prevented both ATP- and nigericin-triggered pyroptosis of human THP-1 cells in a time- and concentration-dependent manner. Moreover, 9 and other structurally related compounds, inhibited caspase-1 and NLRP3 ATPase activities. Our findings can contribute to the development of covalent, multitarget antipyroptotic compounds targeting molecular components of the NLRP3 inflammasome regulatory pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25418070     DOI: 10.1021/jm501072b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

2.  New Highly Potent NLRP3 Inhibitors: Furanochalcone Velutone F Analogues.

Authors:  Ruijia Zhang; Feng Hong; Min Zhao; Xiaoying Cai; Xueqin Jiang; Neng Ye; Kaiyue Su; Na Li; Minghai Tang; Xu Ma; Hengfan Ni; Lun Wang; Li Wan; Lijuan Chen; Wenshuang Wu; Haoyu Ye
Journal:  ACS Med Chem Lett       Date:  2022-03-07       Impact factor: 4.632

Review 3.  The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Hallie M Blevins; Yiming Xu; Savannah Biby; Shijun Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

Review 4.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

5.  Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.

Authors:  Claudia Penna; Manuela Aragno; Alessia Sofia Cento; Saveria Femminò; Isabella Russo; Federica Dal Bello; Fausto Chiazza; Debora Collotta; Gustavo Ferreira Alves; Massimo Bertinaria; Elisa Zicola; Valentina Mercurio; Claudio Medana; Massimo Collino; Pasquale Pagliaro
Journal:  Oxid Med Cell Longev       Date:  2020-08-03       Impact factor: 6.543

6.  Discovery of carbon-11 labeled sulfonamide derivative: A PET tracer for imaging brain NLRP3 inflammasome.

Authors:  Yulong Xu; Yiming Xu; Hallie Blevins; Yu Lan; Yan Liu; Gengyang Yuan; Robin Striar; Julia S Zagaroli; Darcy R Tocci; Amelia G Langan; Can Zhang; Shijun Zhang; Changning Wang
Journal:  Bioorg Med Chem Lett       Date:  2021-01-06       Impact factor: 2.823

7.  Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways.

Authors:  Raffaella Mastrocola; Claudia Penna; Francesca Tullio; Saveria Femminò; Debora Nigro; Fausto Chiazza; Loredana Serpe; Debora Collotta; Giuseppe Alloatti; Mattia Cocco; Massimo Bertinaria; Pasquale Pagliaro; Manuela Aragno; Massimo Collino
Journal:  Oxid Med Cell Longev       Date:  2016-12-08       Impact factor: 6.543

Review 8.  NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies.

Authors:  Limin Song; Lei Pei; Shanglong Yao; Yan Wu; You Shang
Journal:  Front Cell Neurosci       Date:  2017-03-09       Impact factor: 5.505

9.  Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Authors:  Simone Gastaldi; Valentina Boscaro; Eleonora Gianquinto; Christina F Sandall; Marta Giorgis; Elisabetta Marini; Federica Blua; Margherita Gallicchio; Francesca Spyrakis; Justin A MacDonald; Massimo Bertinaria
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 10.  Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation.

Authors:  Tomasz Próchnicki; Matthew S Mangan; Eicke Latz
Journal:  F1000Res       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.